These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2572243)

  • 21. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
    Silke B; Guy S; Humphreys JE
    J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C; Ferrier C; Weidmann P
    J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The place of alpha blockers in the treatment of hypertension.
    Reid JL
    Clin Exp Hypertens; 1993 Nov; 15(6):1291-7. PubMed ID: 7903577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension.
    Davey MJ
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):5S-8S. PubMed ID: 2871856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-blocker therapy of hypertension. An unfulfilled promise.
    Khoury AF; Kaplan NM
    JAMA; 1991 Jul; 266(3):394-8. PubMed ID: 1676077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy.
    Veelken R; Schmieder RE
    Am J Hypertens; 1996 Nov; 9(11):139S-149S. PubMed ID: 8931846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective alpha 1-adrenergic blockade, lipids, and coronary heart disease risk. Considerations in the treatment of mild hypertension.
    Graham RM
    Am J Med; 1989 Aug; 87(2A):53S-56S. PubMed ID: 2569824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia].
    Ponikowski P; Hańczycowa H; Sebzda T; Jurga M; Spring A; Rotter A; Jordanek P
    Wiad Lek; 1993 Apr; 46(7-8):250-4. PubMed ID: 7902632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more?
    Ligueros M; Unwin R; Wilkins M
    Clin Auton Res; 1991 Sep; 1(3):251-8. PubMed ID: 1687998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
    Yasumoto K; Takata M; Yoshida K; Mikawa M; Tomoda F; Sasayama S
    J Hum Hypertens; 1990 Feb; 4(1):13-8. PubMed ID: 1971654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure and lipid lowering effects of terazosin.
    Rosenthal J
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():85-9; discussion 90-1. PubMed ID: 2575179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P; de Courten M; Ferrari P; Böhlen L
    J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha blockers: a reassessment of their role in therapy.
    Cauffield JS; Gums JG; Curry RW
    Am Fam Physician; 1996 Jul; 54(1):263-6, 269-70. PubMed ID: 8677841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.